Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for William D. Keltner
15.79
+0.08 (0.51%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.48 - 15.95
52 week 7.85 - 16.28
Open 15.66
Vol / Avg. 536,971.00/1.06M
Mkt cap 1.27B
P/E     -
Div/yield     -
EPS -0.87
Shares 80.48M
Beta 0.23
Inst. own 53%
Aug 3, 2015
Q2 2015 Raptor Pharmaceutical Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Raptor Pharmaceutical Corp at JMP Securities Life Sciences Conference
Jun 4, 2015
Raptor Pharmaceutical Corp at Jefferies Global Healthcare Conference
May 19, 2015
Raptor Pharmaceutical Corp Annual Shareholders Meeting
May 13, 2015
Raptor Pharmaceutical Corp at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Raptor Pharmaceutical Corp Earnings Call
May 7, 2015
Q1 2015 Raptor Pharmaceutical Corp Earnings Release
Apr 30, 2015
Raptor Pharmaceutical Corp Investor Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -96.24% -75.60%
Operating margin -71.68% -57.63%
EBITD margin - -56.14%
Return on average assets -43.61% -35.29%
Return on average equity -190.93% -135.56%
Employees 123 -
CDP Score - -

Address

7 Hamilton Lndg Ste 100
NOVATO, CA 94949-8246
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product, PROCYSBI delayed-release capsules, received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the EC, as an orphan medicinal product for the management of nephropathic cystinosis in the EU. Its pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. It has product candidates in clinical development designed to potentially treat HD, NASH in children, Leigh syndrome and other mitochondrial disorders and ALDH2. Its preclinical programs are based upon bioengineered drug candidates that are designed to target cancer and other diseases.

Officers and directors

Llew Keltner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Julie Anne Smith President, Chief Executive Officer Designate, Director
Age: 44
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Robert H. Uhl Managing Director
Bio & Compensation  - Reuters
Thomas E Daley Chief Business Officer
Age: 52
Bio & Compensation  - Reuters
David A Happel Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Krishna R. Polu M.D. Chief Medical Officer
Age: 41
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Gregg A. Lapointe C.P.A. Director
Age: 56
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Director
Age: 62
Bio & Compensation  - Reuters